2. Academic Validation
  3. C5 inhibitor avacincaptad pegol treatment for geographic atrophy: A comprehensive review

C5 inhibitor avacincaptad pegol treatment for geographic atrophy: A comprehensive review

  • Immunotherapy. 2024;16(12):779-790. doi: 10.1080/1750743X.2024.2368342.
Carl J Danzig 1 2,  Arshad M Khanani 3 4,  Anat Loewenstein 5
Affiliations

Affiliations

  • 1 Rand Eye Institute, Deerfield Beach, FL 33064, USA.
  • 2 Florida Atlantic University, Charles E. Schmidt College of Medicine, Boca Raton, FL 33431, USA.
  • 3 Sierra Eye Associates, Reno, NV 89502, USA.
  • 4 The University of Nevada, Reno School of Medicine, Reno, NV 89557, USA.
  • 5 Division of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, 6997801, Israel.
PMID: 39073397 DOI: 10.1080/1750743X.2024.2368342
Abstract

Geographic atrophy (GA) remains a leading cause of central vision loss with no known cure. Until recently, there were no approved treatments for GA, often resulting in poor quality of life for affected patients. GA is characterized by atrophic lesions on the retina that may eventually threaten the fovea. Emerging treatments have demonstrated the ability to reduce the rate of lesion growth, potentially preserving visual function. Avacincaptad pegol (ACP; Astellas Pharma Inc), a Complement Component 5 inhibitor, is an FDA-approved treatment for GA that has been evaluated in numerous clinical trials. Here we review the current clinical trial landscape of ACP, including critical post hoc analyses that suggest ACP may reduce the risk of severe loss among patients with GA.

Keywords

C5 inhibition; age-related macular degeneration (AMD); aptamer; avacincaptad pegol (ACP); complement; geographic atrophy (GA); retinal disease.

Figures
Products